Talha Badar: Latest Paper from COMMAND Reports Heterogeneity in Clinical Outcomes in TP53m MPN
Talha Badar, Hematology/Oncology specialist at Mayo Clinic, shared a post on X about a paper he co-authored published in the British Journal of Haematology:
“Latest paper from the COMMAND consortium, reporting heterogeneity in clinical outcomes in TP53m MPN, one of the largest cohorts of TP53m MPN:
- Multihit TP53 had an inferior outcome in chronic phase MPN, not so in MPN-AP or BP. Similar to our reports in HR-MDS/AML.
- MH TP53 is commonly seen in MF or MPN-AP/BP. Rare in PV/ET.
- Allo-HCT improves outcome, less so with MH TP53/complex CG.
- TP53 with low VAF is commonly seen in PV/ET and does not impact disease progression significantly.”
Yu-Hung Wang, PhD student at The University of Manchester, shared this post, adding:
“Very pleased to have been involved in this recent study on TP53-mutated MPN, just out in the British Journal of Haematology. Many thanks to the team for the effort and insight.”
Title: Heterogeneity in outcomes of TP53-mutated myeloproliferative neoplasms based on disease phenotype and mutational status
Authors: Talha Badar, James M. Foran, Jan Philipp Bewersdorf, Yu-Hung Wang, Alexander Coltoff, Mobachir El Kettani, Kashish Shah, Francyess Denis Oliva, Chenyu Lin, Omer Jamy, Kendall Diebold, Rory M. Shallis, Alexa Siddon, Daniil Katkov, Alexa Schoen, Irum Khan, Charles E. Foucar, Ehab Atallah, Aaron D. Goldberg, Anand A. Patel
You can read the Full Article in the British Journal of Haematology.
More posts featuring Talha Badar and Yu-Hung Wang.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023